Member Info for beinthelead

Very honest and valid thought process. I’m with you - it’s been a tough enough ride as it is!

Thanks Lovebug. Nice transcript.

Am I correct in saying he expected TWO LG Chem milestones payment?

Thanks all - appreciated:)

https://avacta.com/wp-content/uploads/2022/04/Avacta-Group-plc-Prelim-Results-2021-FINAL.pdf

April update refers to licensing of AVA6000.

Having a funny moment - can someone point me to where this changed to a wholly owned commodity, ex licensing. Cheers.

Change your name to Poirot. He’s not using it anymore.

Good find. Thanks.

To be fair Timster, CE the only ‘get to market’ requirement. And we nailed that… then realised the market talked up by all and sundry was not there. Hence the rise.

Our rise here will be fuelled by takeover, market size and licensing rumours. We’re some way off commercialisation on our own.

Agreed.

They’re betting on a raise pre-data. No other play on the cards. If it had broken, we’d know by now.

Trojan horse vs Hand grenade.

And in total over 45% is excreted in bile.

Muck by name… :)

Dox is a double-edged sword. It’s tumour response rate is over 70%. But the adverse effects are almost guaranteed at doses required to achieve this efficacy.

Efficacious dose is generally above 60mg/m2. Anything less and you’re not getting any bang for your buck*. But at this level, the limiting factor is the cardiotox threshold. As RAH states, this is LIFETIME limited.

The biggest challenge for oncologists is designing the dose schedule. Variables such as age, weight, height, wellbeing, race, are all factored. As above, They are constrained by that cum. dose limit.

Therefore, if we can increase this lifetime limit, we can exponentially increase ORR and offer greater, less complicated dosing designs. Some that may offer longer periods of lower doses, rather than huge dumps of dox.

In summary; AVA doesn’t have to be a miracle. It just has to allow oncologists greater scope in designing an appropriate dosing regime for the patient. At the current rate, with DE’s it could be assumed we’re headed toward this conclusion.

*https://pubmed.ncbi.nlm.nih.gov/858124/

https://twitter.com/imfreffy/status/1546426384725188610?s=20&t=o1wc97GgqSlI1EE4mMaEYA

What does that mean?

Paul Hill is paid to post his reviews and excitable chat. I’m looking forward to the day when we don’t need it.

There’s people on this board deserve twice the price paid to Paul Hill for their research and promotion. But he has the platform and unfortunate ability to make a lot of mistakes re Avacta.

Blocked. This is pure spam. None of it makes sense. The angle is odd.

Let’s leave it to the guys running the trial - they’re all pretty decent at what they do.

Reported.

Mr A. Don’t let your bias or dislike for posters cloud your judgement here. You’re looking foolish.

Your statement was ABSOLUTE nonsense. This whole free circulating FAP is other places debate has gotten silly.

*genuinely

Lots Timster. I think I’m turning off for a while. He in Ely nothing to see here for a couple of months.

That’s exactly what it is Rip. There’s nothing clever going on here. Avcata need money next year. That’s a fact. How and when they get it is subjective. Data is decisive. I believe data will shock the market and will be comm’d alongside a commercial tie up.

Aiffimers are awesome but they’re a massive bonus at the moment. They are unlikely to generate revenue for years.